The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/Objective-To characterize the relationship between the expression of epidermal growth factor (EGF)-like ligands and vascular nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression and activity in a primate model of atherosclerosis. Methods and Results-Adult male Cynomolgus monkeys were fed a normal or atherogenic (AS) diet for 45 months, after which animals from the AS group were placed on a normal diet for 8 months (regression). The expression of membraneassociated EGF-like ligands was increased in arteries from animals on the AS diet and normalized in the regression group. EGF-like ligands were distributed throughout atherosclerotic vessels but predominantly colocalized with macrophages. Consistent with ligand shedding, circulating heparin-bound EGF was elevated in the plasma of AS monkeys but not in those on regression diet. Atherosclerosis was associated with the activation of EGF receptor signaling. Expression of NADPH oxidase subunits Nox1 and Nox2 but not Nox4 or Nox5 was increased in arteries from monkeys on the AS diet and returned to normal with regression. Levels of Nox1 and Nox2 positively correlated with EGF-like ligands. In cultured monkey smooth muscle cells, treatment with EGF-like ligands increased Nox1 expression and activity.
A therosclerosis is a chronic, complex disease involving many growth factors and cytokines that induce cellular events, such as proliferation, migration, and apoptosis. 1 Epidermal growth factor receptor (EGFR) acts as a switchboard for a diverse array of cellular processes and diseases, 2 but its role in atherosclerosis is poorly defined. In humans, expression of EGFR and 3 of its ligands, heparin-binding epidermal growth factor (HB-EGF), betacellulin, and epiregulin (EREG), is elevated in atherosclerotic plaques. 3, 4 HB-EGF is also increased in plasma from patients with coronary artery disease 5 and correlates with elevated blood cholesterol. 6 In animal models of vascular injury, the targeted inhibition of EGFR or genetic deletion of HB-EGF reduces smooth muscle cell (SMC) proliferation and neointimal formation. 7, 8 These observations suggest a central role for EGFR in atherogenesis; however, the expression pattern of EGF-like ligands in atherosclerosis and the cellular mechanisms by which they contribute to vascular disease are not well characterized.
In cultured vascular cells, EGFR activation is redoxsensitive. [9] [10] [11] Elevated reactive oxygen species (ROS) levels are associated with the pathogenesis of cardiovascular disease 12, 13 and regulate cellularity in the arterial wall through diverse signaling pathways. 14 The predominant source of ROS in vascular cells is nicotinamide adenine dinucleotide phosphate (NADPH) oxidases. 15 In recent years, several studies have linked NADPH oxidase expression with genesis and progression of atherosclerosis in humans [16] [17] [18] and with plaque instability in human coronary arteries. 19 Using a nonhuman primate model of atherosclerosis, we have shown that NADPH oxidase expression and activity are elevated with hypercholesterolemia and decrease after dietary regression. 20 Seven isoforms of the membrane-bound catalytic NADPH oxidase subunits have been identified, of which Nox1, Nox2, Nox4, and Nox5 are relevant to vascular disease. Nox1 is primarily expressed in SMCs, although it has been found in endothelial cells. 21 Nox2 is expressed in endothelial cells, adventitial fibroblasts, inflammatory cells, platelets, and microvascular SMCs. [21] [22] [23] Nox4 is ubiquitously expressed and is the most abundant Nox homolog in vascular cells. 21 Although not normally expressed in inflammatory cells, oxidized low-density lipoprotein induces Nox4 in macrophages. 24 Nox5 is found in endothelial cells 25 and SMCs. 26 We have previously shown that EGFR increases expression of Nox1, 27 but it remains unclear whether EGF-like ligands induce changes in NADPH oxidases in atherosclerosis. We hypothesized that an increase in the expression of EGF-like ligands with atherosclerosis results in an increase in vascular NADPH oxidase activity, and dietary regression normalizes this effect.
In the current study, we used a primate model of atherosclerosis to examine the impact of atherogenic (AS) and regression diets on vascular and circulating EGF-like ligands and vascular NADPH oxidases. Studies were extended to cultured monkey carotid SMCs to determine the effect of EGFlike ligands HB-EGF, amphiregulin (AREG), and EREG on NADPH oxidase expression and activity. These findings suggest that vascular EGFR activation contributes to atherogenesis in part by increasing NADPH oxidase expression and identify EGF-like ligands as potential modulators of vascular disease.
Materials and Methods
Detailed descriptions of all materials and methods are available in the online-only Data Supplement.
Animals
All procedures were approved by the Institutional Animal Care and Use Committee at University of Iowa and complied with the standards stated in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult male Cynomolgus monkeys were obtained from Biomedical Research Foundation (Houston, TX) and housed in an Association for the Assessment and Accreditation of Laboratory Animal Care accredited University Animal Care Facility. Monkeys were fed a normal or AS diet (0.7% cholesterol and 43% of total calories as fat) for 45 months, after which some animals from the AS group were placed on a normal diet for 8 months (regression group) as previously described. 20, 28, 29 These animals were part of a larger group of monkeys that were examined for effects of regression on atherosclerosis as reported elsewhere. 20, 29 All physiological parameters are detailed in Table I in the online-only Data Supplement.
Monkey Carotid SMC Culture
Medial SMCs were isolated from carotid arteries of Cynomolgus monkeys by enzymatic digestion and cultured as described previously. 30 Studies were performed at passages 5 to 10 and 60% to 90% confluence.
Real-Time Polymerase Chain Reaction Analysis
Detection of carotid artery mRNA was performed using quantitative real-time polymerase chain reaction (qRT-PCR) as previously described. 27 Results were quantified and normalized to TATA-box binding protein (TBP) mRNA expression. Primer sequences are listed in Table II in the online-only Data Supplement.
Western Blot Analysis
Expression of aortic HB-EGF, AREG, EREG, Nox1, Nox2, Nox4, Nox5, EGFR, extracellular signal-regulated kinase (ERK), Akt, GAPDH, or TBP and phosphorylation of EGFR, ERK, and Akt were determined by Western blotting with specific antibodies as described in Methods in the online-only Data Supplement.
Immunohistochemistry
Carotid segments were frozen in optimal cutting temperature medium, cut into 10-μm-thick cryosections, incubated with primary antibodies to EGF-like ligands, α-actin, and CD68, then appropriate fluorophoreconjugated secondary antibodies, and visualized by confocal microscopy as described in Methods in the online-only Data Supplement.
ELISA
Concentrations of HB-EGF, AREG, and EREG in plasma were measured by indirect antigen-inhibited ELISA according to the method described for HB-EGF ELISA. 6 All samples were assayed in triplicate.
Measurement of NADPH Oxidase Activity
Cultured SMCs were lyzed, centrifuged at 1000g for 10 minutes, and then supernatant centrifuged at 60 000g for 1 hour (4°C). The pellet was resuspended and superoxide measured by lucigenin-enhanced (5 μmol/L) chemiluminescence (FB12 luminometer, Zylux Corp) after addition of NADPH (300 μmol/L) and normalized to protein. 31 
Measurement of Intracellular Superoxide
Intracellular superoxide levels were detected in SMCs with 10 μmol/L dihydroethidium (DHE) (Invitrogen) as described. 30 DHE fluorescence intensity was visualized with Zeiss LSM 510 META laser confocal microscope and quantified using NIH Image J software.
Statistical Analysis
Results are expressed as mean±SEM. Statistical comparisons were performed by 1-way or 2-way ANOVA with appropriate post hoc analysis. The Pearson correlation statistic was used to measure correlations. P<0.05 was considered significant.
Results

Expression of EGF-Like Ligands in Monkey Vessels
To understand the molecular characteristics of atherosclerosis in nonhuman primates, Cynomolgus monkeys were fed an AS diet for ≈4 years and then transitioned to a normal diet for an additional 8 months (regression). We first examined the expression of EGF-like ligands in carotid arteries of monkeys fed a normal diet, an AS diet, or those in which the AS diet was withdrawn. The AS diet promoted elevated mRNA expression of HB-EGF, AREG, and EREG, whereas levels decreased with regression ( Figure 1A-1C ). EGF expression was not detectable in normal and regression carotids and was low in atherosclerotic samples (data not shown). Protein levels of the membrane-tethered proforms of HB-EGF, AREG, and EREG in aorta were also increased with the development of atherosclerosis and decreased with regression ( Figure 1D-1F ). The various molecular weight bands likely represent differentially glycosylated or N-terminal processed proforms of the ligands. 32, 33 Having shown increased EGF ligand levels, we next examined their distribution in the carotid artery. Immunostaining de monstrated EGF-like ligand expression in each layer of the atherosclerotic vessel wall, with the greatest expression within the plaque region ( Figure 1G ). In comparison, the expression of the EGF-like ligands was barely detectable in the normal and regression vessels ( Figure 1G and Figure I in the onlineonly Data Supplement). Toward understanding the distribution of EGF-like ligands within the vessel wall, we examined the correlation of EGF-like ligand mRNA with markers of specific cell types. Whereas AREG correlated with macrophage colonystimulating factor receptor-1 (MCSFR-1), both AREG and EREG correlated with the monocyte differentiation antigen CD14 ( Figure II in the online-only Data Supplement). Based on these correlations and the AREG expression data in Figure  1A -1G, we next evaluated the cellular localization of AREG within the diseased vessel wall. AREG strongly colocalized with the monocyte/macrophage marker CD68, although it also colocalized with α-actin, a marker of SMCs ( Figure 1H ). This pattern of EGF ligand expression, as demonstrated in Figure 1G and 1H, is consistent with our previous study in which monocytes/macrophages, which are known to express EGF-like ligands, 3 populate the lesion with development of atherosclerosis but are reduced with regression diet. 20 Collectively, our findings indicate that regression diet provides for normalization of the increased levels of EGF-like ligands, in particular AREG and EREG, in atherosclerotic vessels.
Expression of Circulating EGF-Like Ligands in Atherosclerosis
In contrast to the proforms of the EGF-like ligands ( Figure  1D -1F), expression of the mature shed forms was lower in atherosclerotic aorta compared with normal and regression tissues (Figure 2A-2C ). Therefore, we next measured plasma levels of these ligands for evidence of increased shedding. In the plasma from normal monkeys, the level of the EGF-like ligands was highest for AREG and 2 logs lower for EREG ( Figure 2D-2F ). HB-EGF was significantly increased in plasma from monkeys on AS diet compared with those on normal diet, and regression served to normalize levels ( Figure  2D ); a similar though not statistically significant trend was observed with EREG ( Figure 2F ). In contrast, we did not detect a change in circulating AREG levels among the 3 groups ( Figure 2E ).
Activation of EGFR Signaling Pathways
We next assessed whether the observed changes in EGF-like ligand expression were associated with the activation of EGFR and downstream signaling targets. Consistent with ligand expression, EGFR phosphorylation was 50% higher in atherosclerotic arteries compared with normal vessels, and regression promoted a decrease in EGFR phosphorylation to baseline levels ( Figure 2G ). Activation of EGFR by ligand binding triggers a cascade of cellular signaling events, involving the mitogenactivated protein kinase kinase/ERK and phosphoinositide-3 kinase/Akt pathways. Paralleling the activation of EGFR, we found increased phosphorylation of ERK ( Figure 2H ) and Akt ( Figure 2I ) during progression of atherosclerosis and reduction in activation of these signaling pathways after regression diet. Together with our data regarding EGF-like ligand expression in vessels and plasma, these findings indicate that atherosclerosis is associated with increased expression of multiple EGFlike ligands, with subsequent ligand shedding and activation of EGFR signaling pathways. Furthermore, regression diet prevents the increase in EGF-like ligand expression and EGFR pathway activation, despite persistent atherosclerotic lesions.
Expression of NADPH Oxidase Catalytic Subunits
Using murine models of atherosclerosis, we and others have demonstrated that NADPH oxidases contribute to atherogenesis. [34] [35] [36] Activation of EGFR is involved in NADPH oxidase signaling 10 and increases expression of the catalytic NADPH oxidase subunit Nox1. 27 Expression of Nox1 and Nox2 but not Nox4 or Nox5 was elevated at both the mRNA ( Figure  3A ) and protein levels ( Figure 3B ) in atherosclerotic arteries compared with normal vessels. Nox1 and Nox2 levels returned to baseline with regression. Nox1 expression correlated with smooth muscle α-actin expression and Nox2 with monocyte marker CD14 and macrophage marker MCSFR-1 ( Figure III in the online-only Data Supplement); these data are consistent with previously reported cell-specific distribution of these subunits. 17, 18 Recently, expression of both Nox1 37 and Nox4 24 has been shown to be induced in macrophages by low-density lipoprotein or oxidized low-density lipoprotein, respectively. We found a positive correlation between Nox1 but not Nox4 and MCSFR-1 ( Figure III in the online-only Data Supplement). Consistent with the expression pattern of the Nox isoforms in atherosclerosis, we found that the vascular expression of Nox1 and Nox2, but not Nox4 or Nox5, positively correlated with plasma cholesterol levels in monkeys ( Figure 4 ). Together, these data demonstrate a differential expression of Nox subunits in the vessel wall during the active phase of atherosclerosis compared with the regression phase.
EGF-Like Ligand-Dependent Nox Expression
We recently found that activation of the EGFR signaling pathway increases Nox1 expression in murine SMCs. 27 Thus, we first examined whether this relationship between EGFR activation and Nox expression existed in vivo. The expression of Nox1 and Nox2 in the aorta correlated with both circulating and vascular AREG and EREG ( Figure 5 and Figure IV in the online-only Data Supplement). To extend these observations and define causality, we next performed experiments in SMCs isolated from normal monkey carotid arteries. First, we validated that monkey SMCs maintained SMC morphology and differentiation with passage ( Figure V 
Effect of EGF-Like Ligands on NADPH Oxidase Activity
We next determined whether the induction of Nox1 expression by EGF-like ligands is sufficient to increase NADPH oxidase activity in SMCs. These experiments were designed to examine the effect of prolonged EGF-like ligand exposure on ROS production rather than the acute response to the ligands. Corresponding to changes in Nox1 expression, treatment of cultured monkey SMCs with EREG or HB-EGF for 24 hours increased levels of NADPH-stimulated ROS ( Figure 6C ) and cellular ROS ( Figure 6D and Figure VIII in the online-only Data Supplement). AREG failed to increase Nox1 levels or ROS production in cultured SMCs. These data collectively indicate that a subset of EGF-like ligands promotes increased expression and activity of NADPH oxidases in SMCs.
Discussion
Despite a clear role for EGFR activation in the development of multiple diseases, particularly cancer, its role in vascular disease is not well understood. The primary goal of this study was to define the relationship between expression of EGF-like ligands and NADPH oxidases in the development and regression of atherosclerosis. Our data identify multiple novel findings associated with primate atherogenesis: (1) a differential increase in arterial levels of EGF-like ligands AREG, EREG, and HB-EGF; (2) cleavage of vascular EGF-like ligands with a subsequent increase in circulating levels, particularly HB-EGF;
(3) distribution of EGF-like ligands throughout the vessel wall; (4) colocalization of AREG with intimal-residing monocytes/macrophages; (5) increased phosphorylation of vascular EGFR and downstream effectors ERK and Akt; (6) increased expression of vascular Nox1 and Nox2 but not Nox4 or Nox5; and (7) correlation of vascular Nox1 and Nox2 expression with AREG and EREG levels. Despite 4 years of AS diet, an 8-month regression diet was sufficient to normalize the expression, shedding, and activity of EGF-like ligands and Nox1 and Nox2 levels. In addition, HB-EGF and EREG increased Nox1 expression and activity in cultured monkey carotid SMCs. This is the first study to demonstrate a causal link between EGFR activation and NADPH oxidase expression and to identify EGF-like ligands as potential modulators of atherosclerosis.
The expression of AREG and EREG in arteries and HB-EGF in plasma correlated with the development of atherosclerosis in monkeys. Our findings are consistent with previous reports detecting HB-EGF, betacellulin, and EREG in human atherosclerotic plaques 3, 4 and elevated HB-EGF levels in plasma from humans with coronary artery disease. 5 HB-EGF expression and EGFR phosphorylation are increased in a murine model of carotid injury. 8 Our data expand current knowledge by providing comparative analysis of EGF-like ligands in tissue and plasma in a primate model of atherosclerosis. In addition, to the best of our knowledge, this is the first report of increased AREG expression in atherosclerotic vessels and of the therapeutic potential of a regression diet to normalize vascular and circulating EGF-like ligand levels after hypercholesterolemia.
EGF-like ligands are synthesized and expressed on the plasma membrane in immature proforms, and subsequently the juxtamembrane stalk is processed by metalloproteinases to generate the mature forms, which are shed into the extracellular environment. Although the mature forms of EGF-like ligands are classically recognized as the active signaling molecules, the immature forms can also act in a juxtacrine manner to activate receptors on adjacent cells, 38 although this has not been studied in the context of atherosclerosis. We primarily detected the immature EGF-like ligands in monkey atherosclerotic arteries, whereas the mature forms were barely detectable. These observations, combined with the increased tissue mRNA and plasma ligand levels, suggest enhanced expression, processing, and secretion of EGF-like ligands in atherosclerosis. Accordingly, several known EGF-like ligand sheddases (a disintegrin and metalloproteinase-9, 10, and 17) are expressed in human atherosclerotic lesions, [39] [40] [41] and a disintegrin and metalloproteinase-17 is upregulated in a murine model of atherosclerosis. 39 Multiple cell types within the vascular wall have the potential to express EGF-like ligands. HB-EGF is expressed by macrophages, monocytes, T lymphocytes, SMCs, and endothelial cells, whereas AREG and EREG, although less studied, are expressed by monocytes and macrophages. 3 Activated SMCs also have been shown to express EGF-like ligands. 3, 42 Our immunostaining data demonstrate diffuse distribution of the ligands throughout the wall of the atherosclerotic vessel. Of the ligands studied herein, only tissue AREG correlated with markers of SMCs, monocytes, and macrophages. Immunostaining confirmed colocalization of AREG with monocytes/macrophages and to a weaker extent with SMCs. The staining may identify the ligand binding to cells and not necessarily the cellular source of ligand production. Together with our previous data, 20 the decrease in EGF-like ligand levels with regression results primarily from a reduction in macrophage content.
Studies using human atherosclerotic vessels [16] [17] [18] and clinically relevant animal models [34] [35] [36] have analyzed the role of NADPH oxidases in the development and progression of atherosclerosis. Two major findings of our study are that (1) expression of Nox1 and Nox2 but not Nox4 or Nox5 is elevated in monkey atherosclerotic arteries, and (2) Nox1 and Nox2 levels return to normal with regression. Nox1 has a clear role in the activation of SMCs, both in vivo and in vitro. Nox1 is necessary for SMC migration and proliferation, contributing to the development of neointimal hyperplasia. [43] [44] [45] Nox1 has also been associated with endothelial dysfunction 46, 47 and implicated in toll-like receptor-mediated foam cell formation. 37 Further supporting a role for Nox1 in atherogenesis, we have recently shown that deficiency of Nox1 reduces lesion size. 36 Consistent with these observations, we found Nox1 to correlate with α-actin and MCSFR-1 expression, markers of SMCs and macrophages, respectively. In contrast to our findings in this primate model, Nox1 mRNA expression was not increased in patients with severe atherosclerosis. 17, 18 However, these clinical studies did not examine protein levels of Nox1, and studies by our group and others suggest that Nox1 may be more relevant in early stages of disease. 36, 44, 48 Infiltrating monocytes and macrophages are presumed to be the predominant source of increased Nox2 in atherosclerosis; however, Nox2 has also been reported in intimal SMCs in fatty streaks of human aorta. 49 Accordingly, we found Nox2 mRNA to be associated with α-actin, MCSFR-1, and CD14. Furthermore, deletion of Nox2 reduces atherosclerotic lesion size in apolipoprotein E −/− mice. 35 A recent study demonstrated that Nox4 is induced by oxidized low-density lipoprotein in macrophages. 24 In contrast, we saw no increase in Nox4 in atherosclerotic vessels, nor did the expression of Nox4 correlate with markers of monocytes or macrophages. We did not observe an increase in Nox5 with atherosclerosis, which is in contrast to findings in human atherosclerotic coronary arteries. 50 The reason for this apparent discrepancy remains unclear but may be a result of differences in experimental protocols. Specifically, Guzik et al 50 surveyed Nox5 expression in coronary arteries at multiple stages of disease development using an antibody against the second extracellular loop of Nox5. In our study, we sampled Nox5 at a single time point (45-month AS diet) in carotid arteries and aorta using an antibody against the Nox5 EF-hand domain. Further studies will be necessary to identify the contributions of Nox4 and Nox5 to atherogenesis. The genetic deficiency of Nox4 has not been studied in a murine model of atherosclerosis, and the absence of Nox5 in rodents will provide additional challenges.
A primary finding in our study is the relationship between expression of EGF-like ligands and NADPH oxidases in atherosclerosis. In a mouse model of carotid injury, the absence of HB-EGF inhibits intimal thickening and proliferation within the media. 8 However, there is a general lack of data regarding the mechanisms by which EGF-like ligands may contribute to vascular disease. Although our in vivo model precluded demonstration of direct causality between EGFR and NADPH oxidase signaling networks, in cultured SMCs exposure to EGF-like ligands increased Nox1 expression and NADPH oxidase activity. This observation is consistent with our previous findings of increased NADPHstimulated superoxide in carotid arteries with atherosclerosis and a return toward normal with regression. 20 Furthermore, we recently identified a pathway whereby extracellular oxidative stress induces shedding of EGF-like ligands and EGFR activation, culminating in an increase in Nox1 expression. 27 In the current study, we found increased activation of the EGFR downstream effector ERK in atherosclerotic vessels that was reversed with regression. Suggesting a potential mechanism, several studies have shown that ERK activity promotes Nox1 transcription. 27, 51, 52 The interplay between these pathways is complex and potentially bidirectional as there is also evidence that Nox1 activity regulates EGFR expression and transactivation. 11, 53 Our data demonstrate that both AREG and EREG were increased in the vessel and plasma with atherosclerosis and correlated with Nox1 expression. In cultured SMCs, the addition of EREG but not AREG induced Nox1 expression and activity. Potential explanations for the divergent effects of AREG and EREG on Nox1 include differences in ligand-EGFR complex duration and differences in EGFR homo-or heterodimer composition, which are anticipated to alter activation of downstream signaling pathways. Supporting this notion, EREG activation of EGFR was delayed compared with AREG. In addition, the AREG knockout mouse has characteristics that are not observed in knockouts of other EGF-like ligands. 54 Further dissection of the role of individual EGF-like ligands in vascular cell activation is necessary to determine whether the ligands have a direct role in development of atherosclerosis.
Using a long-term primate model of atherosclerosis, we demonstrate a relationship between EGF-like ligands and vascular NADPH oxidase in disease. Our studies identify differential regulation of ligands and Nox expression in atherosclerosis. The observation that dietary interventions to reduce hypercholesterolemia are sufficient to normalize EGFlike ligand and NADPH oxidase levels establishes the reversibility of these pathological effects. Our findings suggest that EGF-like ligands may serve as biomarkers for active inflammatory atherosclerosis and provide the rationale for additional studies to determine whether currently available EGFR inhibitors have therapeutic benefit.
